Pluri Inc.

Regulatory Filings • Nov 18, 2020

PSTI 8K Phase I HCT Study (November 2020) false

�������� ��������� ����	2 380
PLURISTEM THERAPEUTICS INC
Corporation no: C12337-2001	8543
- - -

	Israel Securities Authority			Tel Aviv Stock Exchange		C002 ( Public )		Reported via MAGNA:	18/11/2020
	www.isa.gov.il			www.tase.co.il				Reference:	2020-02-115849	Time of broadcast: 15:00 15:00

---

Immediate ReportRegulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000

	The corporation is a foreign private issuer as defined by U.S. Securities Laws.

Attached hereto is a report onPSTI 8K Phase I HCT Study (November 2020)

PSTI_8K_Phase_I_HCT_Study_November_2020_isa.pdf

References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
- - -
Stock Exchange/Market: NASDAQ CM	Date of revision of form structure: 27/10/2020
Address: Matam Park 5 , Haifa 31905   ISRAEL , Tel: 074-7107171 , Fax: 074-7107172
E-mail address: Info@Pluristem.Com   Company site: www.pluristem.com
Previous names of reporting entity:
Name of the Signatory: Yanay Yaacov Position of Signatory in the reporting corporation: Chief Executive Officer, Director Name of Employer Company:
Address: Matam Park 5 , Haifa 31905 Telephone: 074-7107171 Facsimile: 074-7108673 E-mail: yaky@pluristem.com 1